First, the eligibility of patients is determined prior to treatment based on MAGE-A3 expression; in such studies, this has often been assessed at the gene level by quantitative RT-PCR, but nothing is known about expression at the protein level or the actual number of MAGE-A3-positive cancer cells. This evidence concerns the gene MAGEA3 and cancer.